MedTrace Logo

Immune Responses After a Four-site Intradermal Rabies Booster Vaccination in HIV-infected Adults

NCT02547727 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2022-04-29

No results posted yet for this study

Summary

A four-site intradermal rabies booster vaccination in HIV - infected patients who have ever received primary rabies vaccination could improve their immune response to this kind of vaccine.

Conditions

  • Rabies

Interventions

BIOLOGICAL

rabies vaccine

Rabies vaccine is injected according to the protocol then blood would be drawn for rabies neutralizing antibody, OX-40 assay and cytokines assessment on day 0,7,14.

Sponsors & Collaborators

  • Chulalongkorn University

    collaborator OTHER

  • Queen Saovabha Memorial Institute

    lead OTHER

Principal Investigators

  • Suda Sibunruang, MD · Queen Saovabha Memorial Institute. Faculty of Medicine, Chulalongkorn university

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02547727 on ClinicalTrials.gov